The effect of surgery on fat mass, lipid and glucose metabolism in mild primary hyperparathyroidism

Endocrine Connections
Kristin GodangAnsgar Heck

Abstract

Mild primary hyperparathyroidism has been associated with increased body fat mass and unfavorable cardiovascular risk factors. To assess the effect of parathyroidectomy on fat mass, glucose and lipid metabolism. Design, Patients, Interventions, Main outcome measures: 119 patients previously randomized to observation (OBS; n=58) or parathyroidectomy (PTX; n=61) within the Scandinavian Investigation of Primary Hyperparathyroidism (SIPH) trial, an open randomized multicenter study, were included. Main outcome measures for this study were the differences in fat mass, markers for lipid- and glucose metabolism between OBS and PTX five years after randomization. In the OBS group, total cholesterol (Total-C) decreased from mean 5.9 (±1.1) to 5.6 (±1.0) mmol/l (P=0.037) and LDL-Cholesterol (LDL-C) decreased from 3.7 (±1.0) to 3.3 (±0.9) mmol/l (P=0.010). In the PTX group, the Total-C and LDL-C remained unchanged resulting in a significant between group difference over time (P=0.013 and P=0.026, respectively). This difference was driven by patients who started with lipid lowering medication during the study period (OBS: 5; PTX: 1). There was an increase in trunk fat mass in the OBS group, but no between group differences over time. Mean ...Continue Reading

References

Jun 1, 1996·The Journal of Clinical Endocrinology and Metabolism·B G Leifsson, B Ahrén
Aug 11, 1998·The European Journal of Surgery = Acta Chirurgica·E B CollianderJ Nordenström
Jun 26, 2001·Diabetes/metabolism Research and Reviews·W H Taylor, A A Khaleeli
Jun 7, 2003·Endocrine-related Cancer·N Garcia de la TorreH E Turner
Dec 23, 2004·The Journal of Clinical Endocrinology and Metabolism·Mark J BollandIan R Reid
Feb 8, 2007·The Journal of Clinical Endocrinology and Metabolism·Jens BollerslevThord Rosen
May 31, 2007·The Journal of Clinical Endocrinology and Metabolism·Elena AmbroginiClaudio Marcocci
Apr 9, 2009·The Journal of Clinical Endocrinology and Metabolism·Jens BollerslevUNKNOWN SIPH Study Group
Nov 4, 2010·Clinical Endocrinology·Anita PerssonUNKNOWN SIPH Study Group
Aug 28, 2014·The Journal of Clinical Endocrinology and Metabolism·John P BilezikianJohn T Potts
Aug 28, 2014·The Journal of Clinical Endocrinology and Metabolism·Shonni J SilverbergJohn P Bilezikian
Jan 31, 2015·The Journal of Clinical Endocrinology and Metabolism·Karolina LundstamUNKNOWN SIPH Study Group
Nov 22, 2016·Indian Journal of Endocrinology and Metabolism·Rachel PutnamSanjay Kumar Bhadada
Sep 3, 2017·European Journal of Endocrinology·Jessica PepeSalvatore Minisola

❮ Previous
Next ❯

Citations

Dec 24, 2018·British Medical Bulletin·Zaki K Hassan-SmithNeil J L Gittoes

❮ Previous
Next ❯

Methods Mentioned

BETA
X-ray

Software Mentioned

Lunar Prodigy densitometer
Lunar DPX - L

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

Asprosin

Asprosin is a fasting-induced hormone produced in the white adipose tissue to stimulate the hepatic release of glucose into the bloodstream. Discover the latest research on this protein hormone here.

© 2022 Meta ULC. All rights reserved